Gerald Downey

1.7k total citations
19 papers, 864 citations indexed

About

Gerald Downey is a scholar working on Oncology, Infectious Diseases and Immunology. According to data from OpenAlex, Gerald Downey has authored 19 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Infectious Diseases and 4 papers in Immunology. Recurrent topics in Gerald Downey's work include CAR-T cell therapy research (5 papers), HIV/AIDS Research and Interventions (4 papers) and Immunotherapy and Immune Responses (4 papers). Gerald Downey is often cited by papers focused on CAR-T cell therapy research (5 papers), HIV/AIDS Research and Interventions (4 papers) and Immunotherapy and Immune Responses (4 papers). Gerald Downey collaborates with scholars based in United Kingdom, United States and Switzerland. Gerald Downey's co-authors include Kevin J. Harrington, Robert H.I. Andtbacka, Frances A. Collichio, Howard L. Kaufman, Katarina Öhrling, Mark R. Middleton, Peter Reichardt, Emanuela Palmerini, Piero Picci and Mark Rowland and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and AIDS.

In The Last Decade

Gerald Downey

19 papers receiving 848 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerald Downey United Kingdom	14	405	221	205	174	106	19	864
Siobhán O’Connor United States	19	221 0.5×	90 0.4×	182 0.9×	284 1.6×	91 0.9×	51	1.1k
Saaïd Amzazi Morocco	16	94 0.2×	158 0.7×	79 0.4×	301 1.7×	199 1.9×	54	838
Xiaojun Li China	12	166 0.4×	56 0.3×	52 0.3×	287 1.6×	267 2.5×	25	756
Sheryl L. Henderson United States	13	81 0.2×	103 0.5×	431 2.1×	460 2.6×	84 0.8×	26	1.1k
Emily S. Ford United States	12	226 0.6×	81 0.4×	86 0.4×	194 1.1×	171 1.6×	29	764
George Silva Brazil	15	79 0.2×	110 0.5×	53 0.3×	324 1.9×	149 1.4×	38	778
Allyson Guimarães Costa Brazil	17	66 0.2×	178 0.8×	161 0.8×	150 0.9×	107 1.0×	85	787
Sarika Jain United States	16	417 1.0×	44 0.2×	119 0.6×	160 0.9×	382 3.6×	49	1.1k
Jéssica Cristina dos Santos Netherlands	15	77 0.2×	60 0.3×	416 2.0×	108 0.6×	127 1.2×	42	684
Ana Salinas Spain	15	86 0.2×	63 0.3×	114 0.6×	423 2.4×	82 0.8×	35	800

Countries citing papers authored by Gerald Downey

Since Specialization

Citations

This map shows the geographic impact of Gerald Downey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Downey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Downey more than expected).

Fields of papers citing papers by Gerald Downey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Downey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Downey. The network helps show where Gerald Downey may publish in the future.

Co-authorship network of co-authors of Gerald Downey

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Downey. A scholar is included among the top collaborators of Gerald Downey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Downey. Gerald Downey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Andtbacka, Robert H.I., Frances A. Collichio, Kevin J. Harrington, et al.. (2019). Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. Journal for ImmunoTherapy of Cancer. 7(1). 145–145. 301 indexed citations

Palmerini, Emanuela, Piero Picci, Peter Reichardt, & Gerald Downey. (2019). Malignancy in Giant Cell Tumor of Bone: A Review of the Literature. Technology in Cancer Research & Treatment. 18. 1078107648–1078107648. 99 indexed citations

Mohr, Peter, Sebastian Haferkamp, Andreas Pinter, et al.. (2018). Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey. Advances in Therapy. 36(1). 101–117. 18 indexed citations

Gutzmer, Ralf, Kevin J. Harrington, Christoph Höeller, et al.. (2018). Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. European Journal of Dermatology. 28(6). 736–749. 10 indexed citations

Stevens, John, et al.. (2017). A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence. Research Synthesis Methods. 9(2). 148–162. 20 indexed citations

Krieken, J. Han van, George Kafatos, James A. Bennett, et al.. (2017). Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review. BMC Cancer. 17(1). 798–798. 6 indexed citations

Chesney, Jason, Sanjay Awasthi, Brendan D. Curti, et al.. (2017). Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma. Melanoma Research. 28(1). 44–51. 32 indexed citations

Brauer, Ruth, Ian Douglas, Luis A. Garcı́a Rodrı́guez, et al.. (2016). Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case–control studies using two primary care databases in Europe. Pharmacoepidemiology and Drug Safety. 25(S1). 29–38. 13 indexed citations

Mt‐Isa, Shahrul, Edmond S. Chan, Gerald Downey, et al.. (2016). Recommendations for benefit–risk assessment methodologies and visual representations. Pharmacoepidemiology and Drug Safety. 25(3). 251–262. 56 indexed citations

10.

Harrington, Kevin J., Robert H.I. Andtbacka, Frances A. Collichio, et al.. (2016). Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. OncoTargets and Therapy. Volume 9. 7081–7093. 73 indexed citations

11.

Hallgreen, Christine E., Shahrul Mt‐Isa, A Lieftucht, et al.. (2015). Literature review of visual representation of the results of benefit–risk assessments of medicinal products. Pharmacoepidemiology and Drug Safety. 25(3). 238–250. 18 indexed citations

12.

Trojan, Jörg, Laurent Mineur, Jiří Tomášek, et al.. (2015). Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. PLoS ONE. 10(10). e0140717–e0140717. 7 indexed citations

13.

Mt‐Isa, Shahrul, Edmond S. Chan, Gerald Downey, et al.. (2014). IMI-PROTECT benefit-risk grouprecommendations report:recommendations for the methodology andvisualisation techniques to be used in theassessment of benefit and risk of medicines. London School of Economics and Political Science Research Online (London School of Economics and Political Science). 13 indexed citations

14.

Collier, Ann C., Camlin Tierney, Gerald Downey, et al.. (2008). Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV. HIV Clinical Trials. 9(2). 91–102. 8 indexed citations

15.

Benson, Constance A., Florin Vaida, Diane V. Havlir, et al.. (2006). A Randomized Trial of Treatment Interruption before Optimized Antiretroviral Therapy for Persons with Drug‐Resistant HIV: 48‐Week Virologic Results of ACTG A5086. The Journal of Infectious Diseases. 194(9). 1309–1318. 18 indexed citations

16.

Kashuba, Angela D. M., Camlin Tierney, Gerald Downey, et al.. (2005). Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 19(2). 145–152. 48 indexed citations

17.

Rowland, Mark, Tim Freeman, Gerald Downey, Abdul Hadi, & Mohammed Saeed. (2004). DEET mosquito repellent sold through social marketing provides personal protection against malaria in an area of all‐night mosquito biting and partial coverage of insecticide‐treated nets: a case–control study of effectiveness. Tropical Medicine & International Health. 9(3). 343–350. 42 indexed citations

18.

Rowland, Mark, Gerald Downey, Abdur Rab, et al.. (2004). DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan. Tropical Medicine & International Health. 9(3). 335–342. 78 indexed citations

19.

Bosch, Ronald J., Gerald Downey, David Katzenstein, et al.. (2003). Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS. 17(16). 2395–2396. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact